GE Vernova T&D India Limited (NSE:GVT&D)

Ligand Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	4,728	1,319	446.7	708	489.5
Short-Term Investments	-	-	12.6	8.5	99.5	92.2
Cash & Short-Term Investments	4,728	4,728	1,332	455.2	807.5	581.7
Cash Growth	252.59%	254.97%	192.62%	-43.63%	38.82%	-16.29%
Accounts Receivable	-	14,689	16,115	17,582	17,254	21,701
Other Receivables	-	-	19.1	0.3	1.5	4.6
Receivables	-	20,473	17,562	17,583	17,255	21,705
Inventory	-	7,035	5,892	6,439	6,226	5,796
Prepaid Expenses	-	-	94.8	86.3	103.4	91
Other Current Assets	-	4,489	1,462	2,093	2,869	1,903
Total Current Assets	-	36,725	26,343	26,656	27,261	30,077
Property, Plant & Equipment	-	4,190	4,041	4,222	4,579	5,145
Long-Term Investments	-	-	-	-	0.1	0.1
Other Intangible Assets	-	1	0.4	0.8	1.3	7.9
Long-Term Deferred Tax Assets	-	1,270	1,018	1,340	1,470	1,248
Other Long-Term Assets	-	4,425	4,443	4,577	4,363	4,213
Total Assets	-	46,611	35,844	36,795	37,674	40,691
Accounts Payable	-	10,259	8,856	10,607	11,110	11,162
Accrued Expenses	-	-	1,144	862.4	822.3	883.2
Short-Term Debt	-	-	4.3	2,198	1,634	2,213
Current Portion of Leases	-	134.7	115.3	123.8	113.5	128.5
Current Income Taxes Payable	-	611.9	371	181.7	212.1	212.2
Current Unearned Revenue	-	-	7,381	6,196	5,658	7,458
Other Current Liabilities	-	16,892	4,638	4,468	5,779	5,198
Total Current Liabilities	-	27,897	22,510	24,636	25,329	27,254
Long-Term Leases	-	210.9	298.6	411.6	511.2	819.5
Other Long-Term Liabilities	-	771.5	185.5	583.7	693.6	991.3
Total Liabilities	-	28,880	23,415	26,068	26,871	29,464
Common Stock	-	512.1	512.1	512.1	512.1	512.1
Additional Paid-In Capital	-	-	2,718	2,718	2,718	2,718
Retained Earnings	-	-	9,343	7,532	7,547	7,971
Comprehensive Income & Other	-	17,219	-143.2	-35	25.9	26.5
Shareholders' Equity	17,731	17,731	12,429	10,727	10,803	11,227
Total Liabilities & Equity	-	46,611	35,844	36,795	37,674	40,691
Total Debt	345.6	345.6	418.2	2,733	2,259	3,161
Net Cash (Debt)	4,383	4,383	913.8	-2,278	-1,452	-2,579
Net Cash Growth	374.92%	379.60%	-	-	-	-
Net Cash Per Share	17.12	17.12	3.57	-8.90	-5.67	-10.07
Filing Date Shares Outstanding	256.11	256.17	256.05	256.05	256.05	256.05
Total Common Shares Outstanding	256.11	256.17	256.05	256.05	256.05	256.05
Working Capital	-	8,827	3,833	2,020	1,932	2,823
Book Value Per Share	69.22	69.22	48.54	41.90	42.19	43.85
Tangible Book Value	17,730	17,730	12,429	10,726	10,802	11,219
Tangible Book Value Per Share	69.21	69.21	48.54	41.89	42.19	43.82
Land	-	-	425.2	425.2	425.3	495.1
Buildings	-	-	2,527	2,483	2,642	2,949
Machinery	-	-	3,814	3,586	4,915	4,936
Construction In Progress	-	-	110.6	92.1	89.6	216.6
Order Backlog	-	-	62,700	36,900	37,227	45,903

Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.